A randomised study to optimise clinical outcomes in patients with FLT3 mutant AML

急性髓系白血病是一种毁灭性的血癌，每年影响近1000澳大利亚人。四分之一的人有一种突变，影响一种名为Flt3的基因，这种基因导致侵袭性白血病，仅靠化疗很难治愈。阿尔弗雷德医院的安德鲁·韦博士将通过澳大利亚白血病和淋巴瘤小组网络领导一项全国性的随机临床试验，以调查名为Sorafenib的靶向Flt3抑制剂小分子是否会改善这种低风险血癌患者的预后。

Acute myeloid leukaemia is a devastating blood cancer which affects almost 1000 Australians annually. One quarter have a mutation affecting a gene called FLT3, which results in aggressive leukaemia rarely cured by chemotherapy alone. Dr Andrew Wei from the Alfred Hospital will lead a nationwide randomised clinical trial through the Australasian Leukaemia and Lymphoma Group network to investigate whether a targeted FLT3 inhibitor small molecule called Sorafenib will improve outcomes for patients with this poor risk blood cancer.